Critical Innovations is currently developing multiple medical devices toward regulatory clearance. The company focuses on task-shifting evidence-based interventions to earlier echelons of care and more general specialty levels, to simplify management and allow for rapid provision in emergency and combat environments. To date, the company has worked under more than 20 different Department of Defense awards from all three military branches charged with medical technology development (i.e. U.S. Army, Air Force, and Navy), including such agencies as the Air Force Medical Support Agency; Army Medical Research and Development Command; Defense Health Agency; and, Office of Naval Research. Contract types have included Small Business Innovation Research (SBIR), Joint Warfighter, and Other Transactional Authority. As a prime contractor, Critical Innovations currently has a 100% transition rate from Phase I to Phase II, as well as Phase II to Phase III, for all eligible SBIR programs.
An editorial by Critical Innovations' President & CEO, Dr. Ross Donaldson, and other supporters of improved trauma research and development funding was published in the journal Trauma Surgery & Acute Care Open focusing on the divergence of military and civilian trauma research priorities. See the full article here.
Severe intra-abdominal bleeding currently requires operative treatment by trained surgeons, while Critical Innovations' patented F.O.A.M.™ technology task-shifts to allow earlier abdominal hemostasis
Critical Innovations is happy to announce that it recently signed a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Combat Capabilities Development Command Chemical Biologica